Spotlight on Cerebrolysin in Dementia
- PDF / 108,107 Bytes
- 4 Pages / 504.57 x 720 pts Page_size
- 69 Downloads / 173 Views
ADIS SPOTLIGHT
ª 2010 Adis Data Information BV. All rights reserved.
Spotlight on Cerebrolysin in Dementiay Greg L. Plosker1 and Serge Gauthier2 1 Adis, a Wolters Kluwer Business, Auckland, New Zealand 2 McGill Center for Studies in Aging, Montre´al, Que´bec, Canada
Contents Abstract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Pharmacological Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Therapeutic Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abstract
263 263 264 264
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks’ duration in patients with Alzheimer’s disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability. A large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global measures and cognition for all three treatment groups compared with baseline. Although not as extensively studied in patients with vascular dementia, Cerebrolysin has also shown beneficial effects on global measures and cognition in this patient population. Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event. Although further studies with Cerebrolysin, including longer term trials and further exploration of its use in combination with cholinesterase inhibitors, are needed to more clearly determine its place in the management of Alzheimer’s disease and vascular dementia, available data suggest that Cerebrolysin is a useful addition to the treatment options available for dementia.
1. Pharmacological Properties Several in vitro and in vivo studies have shown that Cerebrolysin has neurotrophic effects similar to those of endogenous neurotrophic factors.
Cerebrolysin improved the viability of cultured neurons in vitro[1] and rescued medial septal cholinergic neurons following intraperitoneal administration in rats after transections of fimbria-fornix in the brain.[2] Peripheral administration of Cerebrolysin also
y Derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs & Aging 2009; 26 (11): 893–915. The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.
Plosker & Gauthier
264
p
Data Loading...
